Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Syndax Pharmaceuticals Q4 EPS $(0.62) Beats $(0.65) Estimate

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share
byBill Haddad
February 28, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Reported Late Wednesday, Moderna Finalizes Strategic Partnership With U.K Government; The 10-Year Strategic Partnership Is Expected To Provide The U.K Public With Response Capabilities To Ensure Future Preparedness In Light Of The Covid-19 Pandemic

By Benzinga Newsdesk
Today, 9:54 AM
Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure The ten-year strategic partnership is expected to provide the UK public with response

EWU